News
The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.
Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...
BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...
Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...
BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results